Elan to Pay Shareholders Tysabri Dividends in Challenge to Bid

Elan Corp. (ELN) said it will pay shareholders dividends from its royalties from multiple- sclerosis drug Tysabri in a challenge to a $6.5 billion bid from RP Management LLC for the Dublin-based drugmaker.

Biogen Idec Inc. on Feb. 6 agreed to buy Elan’s stake in the Tysabri drug for $3.25 billion in cash plus future royalties. The drug generated $1.6 billion in sales in 2012. Elan said today it will pay shareholders dividends directly linked to Tysabri’s market performance as a 20 percent share of the royalty received from Biogen Idec.

RP Management offered to buy Elan on Feb. 25, saying a sale would allow shareholders to avoid the substantial risks of Chief Executive Officer Kelly Martin’s plan to make purchases with the proceeds from Tysabri.

Martin said today that together with a $1 billion share- repurchase program announced Feb. 22 and plans to buy additional drug assets, the dividend provides shareholders “significant near- and longer-term benefits.”

To contact the reporter on this story: Kim McLaughlin in Stockholm at kmclaughlin6@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.